Loading
Latest filing published 23 Aug 2021 for Baudax Bio, Inc., €22k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Richard S. Casten, listed as finance chief, appears in our data through filings on Baudax Bio, Inc. shares, published by SEC (Form 4). The record holds 5 filings, for trades running from 8 March 2021 to 20 August 2021.
On the market, this insider has only ever bought: 3 purchases, €68k in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 2 share grants.
Half of the purchases are above €22k and half below. Of 3 purchases, 1 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
The newest entry dates from 23 August 2021: an open-market purchase of €22k, in Baudax Bio, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations